← Leaderboards
Robert T Dorr
University Of Arizona
$3,942,329
Attributed
$3,942,329
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2M · FY2005–13$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$17,623,759 · 8
By mechanism
P01$15,057,183 · 4
P30$1,329,268 · 2
R01$940,556 · 1
U54$296,752 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Arizona
Same institution · by research overlap
- Michael P. Doyle$3,036,142
- William R. Montfort$14,116,391
- Jeannie Kim Lee$3,070,501
- Anna R Giuliano$35,098,080
- Jesse D. Martinez$8,830,642
Others in their field
Top investigators on “Biomedical Facility”
- David Heimbrook · Leidos Biomedical Research, Inc.$269,207,281
- Mark S Klempner · Tufts Medical Center$133,377,807
- Joseph E Robertson · Oregon Health & Science University$129,896,064
- Lee Hamm · Tulane University Of Louisiana$114,986,978
- Peter Gordon Gillespie · Oregon Health And Science University$108,298,240
- Jeffrey S Flier · Beth Israel Deaconess Medical Center$90,163,926
Research focus
Biomedical FacilityPancreasImexonPlasmaMalignant Neoplasm Of PancreasMutationOxidation-ReductionGrowthCellsOxidationIn VivoAziridinesBaseMultiple MyelomaPharmaceutical PreparationsIn VitroEnvironmentGemcitabineReactive Oxygen SpeciesApoptosisAnalogCancer CellClinical TrialsResponse
Grant awards (34)
Program Leaders$190,515
P30 · FY2013 · CA · contact PI
Program Leaders$75,000
P30 · FY2013 · CA · contact PI
Program Leaders$210,013
P30 · FY2012 · CA · contact PI
Therapeutic Targeting of Hypoxic and Oxidative Stress$1,268,395
P01 · FY2011 · CA · contact PI
TARGETING OXIDATIVE STRESS IN HUMAN PANCREATIC CANCER$240,339
P01 · FY2011 · CA · contact PI
Program Leaders$225,623
P30 · FY2011 · CA · contact PI
Therapeutic Targeting of Hypoxic and Oxidative Stress$1,307,594
P01 · FY2010 · CA · contact PI
TARGETING OXIDATIVE STRESS IN HUMAN PANCREATIC CANCER$247,253
P01 · FY2010 · CA · contact PI
Program Leaders$244,410
P30 · FY2010 · CA · contact PI
Therapeutic Targeting of Hypoxic and Oxidative Stress$1,281,955
P01 · FY2009 · CA · contact PI
TARGETING OXIDATIVE STRESS IN HUMAN PANCREATIC CANCER$241,898
P01 · FY2009 · CA · contact PI
Redox-Active Agents for Pancreatic Cancer$234,227
R01 · FY2009 · CA · contact PI
Program Leaders$233,487
P30 · FY2009 · CA · contact PI
Therapeutic Targeting of Hypoxic and Oxidative Stress$1,244,592
P01 · FY2008 · CA · contact PI
TARGETING OXIDATIVE STRESS IN HUMAN PANCREATIC CANCER$234,334
P01 · FY2008 · CA · contact PI
Redox-Active Agents for Pancreatic Cancer$234,227
R01 · FY2008 · CA · contact PI
Therapeutic Targeting of Hypoxic and Oxidative Stress$1,249,645
P01 · FY2007 · CA · contact PI
Redox-Active Agents for Pancreatic Cancer$234,227
R01 · FY2007 · CA · contact PI
TARGETING OXIDATIVE STRESS IN HUMAN PANCREATIC CANCER$229,082
P01 · FY2007 · CA · contact PI
ADMINISTRATIVE CORE$78,313
P01 · FY2007 · CA · contact PI
NEW DRUG TARGETS FOR APOPTOSIS$498,959
P01 · FY2006 · CA · contact PI
Redox-Active Agents for Pancreatic Cancer$237,875
R01 · FY2006 · CA · contact PI
NEW DRUG TARGETS FOR APOPTOSIS$1,446,246
P01 · FY2005 · CA
NEW DRUG TARGETS FOR APOPTOSIS$1,405,759
P01 · FY2004 · CA
NEW DRUG TARGETS FOR APOPTOSIS$1,357,166
P01 · FY2003 · CA
NEW DRUG TARGETS FOR APOPTOSIS$1,329,187
P01 · FY2002 · CA
Core--Pharmacology$296,752
U54 · FY2002 · CA
CORE--RESEARCH PHARMACY SERVICE$0
P30 · FY2002 · CA
NEW DRUG TARGETS FOR APOPTOSIS$1,291,932
P01 · FY2001 · CA
Core--Pharmacology$0
U54 · FY2001 · CA
CORE--RESEARCH PHARMACY SERVICE$0
P30 · FY2001 · CA
CORE--TOXICOLOGY AND FORMULATION CORE$0
P01 · FY2001 · DA
CORE--RESEARCH PHARMACY SERVICE$150,220
P30 · FY2000 · CA
CORE--TOXICOLOGY AND FORMULATION CORE$104,534
P01 · FY2000 · DA